Looking beyond COVID-19 vaccine phase 3 trials
Looking beyond COVID-19 vaccine phase 3 trials
复制标题
DOI：
10.1038/s41591-021-01230-y
复制
发表时间：
2021-01-19
期刊：
影响因子：
82.9
通讯作者：
Clemens, John D.
中科院分区：
文献类型：
--
作者：
Kim, Jerome H.;Marks, Florian;Clemens, John D.
在最近几家制造商宣布COVID-19疫苗在临床试验中对预防严重疾病的有效性后，现在需要为下一步措施制定全面的有效性后策略，以确保全球人口接种疫苗。这些考虑应包括如何制造数十亿剂高质量疫苗、支持疫苗采购、协调供应、公平分配疫苗以及全球疫苗交付的后勤保障，所有这些都是针对所有年龄段人群的大规模疫苗接种运动的前奏。此外，为提高疫苗效力，还应回答关于疫苗的其他科学问题，包括关于优化疫苗接种方案、加强剂量、保护的相关性、疫苗有效性、安全性和加强监测的问题。及时和协调地执行这些效力后任务将有效和高效地结束这场大流行病。
After the recent announcement of COVID-19 vaccine efficacy in clinical trials by several manufacturers for protection against severe disease, a comprehensive post-efficacy strategy for the next steps to ensure vaccination of the global population is now required. These considerations should include how to manufacture billions of doses of high-quality vaccines, support for vaccine purchase, coordination of supply, the equitable distribution of vaccines and the logistics of global vaccine delivery, all of which are a prelude to a massive vaccination campaign targeting people of all ages. Furthermore, additional scientific questions about the vaccines remain that should be answered to improve vaccine efficacy, including questions regarding the optimization of vaccination regimens, booster doses, the correlates of protection, vaccine effectiveness, safety and enhanced surveillance. The timely and coordinated execution of these post-efficacy tasks will bring the pandemic to an effective, and efficient, close.